Biotech Startups

Alteron Therapeutics is a pharmaceutical company focused on drug innovation. The available page does not detail its specific therapeutic areas or products.

1 investor

Altratech develops point-of-care diagnostic technology for quantitative HIV viral load testing in low- and middle-income countries. The company creates affordable and accessible medical devices for resource-limited healthcare settings.

1 investor

Altrovia builds an AI agent for clinical trial development that combines evidence retrieval, reasoning, and automated review to help teams analyze and benchmark study designs against comparable trials. It supports clinical development teams in assessing trial complexity, endpoints, and regulatory gaps.

1 investor

Altum Sequencing develops ultra-sensitive, tumor-informed liquid biopsy (ctDNA) tests paired with an AI-driven platform to detect cancer relapse and measure treatment response at the molecular level. It serves clinicians and researchers in oncology and hematology, covering both hematologic malignancies and solid tumors.

1 investor

Alume Biosciences develops nerve illumination technology for surgery, including bevonescein (ALM-488), an injectable peptide that makes nerves glow to help surgeons identify and preserve them during procedures such as head-and-neck and prostate surgery. The drug candidate is in Phase 3 clinical trials, with a planned FDA New Drug Application submission in 2026.

1 investor

AlveoGene develops respiratory gene therapies, led by executives and academic researchers from the UK Respiratory Gene Therapy Consortium.

1 investor

Alveolus Bio develops inhaled biotherapeutics for chronic and infectious lung diseases, using a platform that delivers targeted bacteria to the lungs to treat conditions such as idiopathic pulmonary fibrosis, NCFBE, and COPD. It serves patients with chronic and infectious respiratory conditions in the biotechnology and pharmaceutical space.

1 investor

Alveus Pharmaceuticals is a pharmaceutical development company specializing in niche generic and specialty pharmaceutical products through internal product development and late-stage licensing. Based in Hyderabad, the company provides contract development services with a focus on affordability, safety, and compliance with international quality standards.

1 investor

Alvogen is a pharmaceutical company committed to making high-quality medicines more accessible through a focus on best people, portfolio, service, quality, and cost efficiency. The company serves customers globally in the pharmaceutical industry.

1 investor

Alvogen Korea is a pharmaceutical company that develops and supplies prescription and over-the-counter medicines covering obesity, central nervous system, kidney, and cardiovascular disease areas. It operates in the South Korean pharmaceutical market, relying on quality control, supply systems, and global partner networks.

1 investor

Alyssum is a biotechnology company developing novel therapeutic drugs, with expertise in protein engineering, oncology, and clinical development. Its leadership includes veterans of multiple FDA-approved medicines and accelerated approvals.

1 investor

Alzinova is a clinical-stage biopharmaceutical company developing an active immunotherapy (vaccine) for Alzheimer's disease based on its proprietary AβCC Peptide technology. The company's lead candidate is in clinical testing in patients, and its shares are listed on Nasdaq First North Growth Market in Stockholm.

1 investor

Alzprotect is a biotech company developing therapeutic candidates for neurodegenerative diseases, including tauopathies such as Progressive Supranuclear Palsy (PSP) and Alzheimer's disease. Its lead drug candidate targets multiple markers of neurodegeneration including amyloid beta peptide, Tau protein, neuroinflammation, and oxidative stress.

1 investor

Alzyn is a nutrigenomics company that develops patented transdermal supplements aimed at protecting brain health, boosting immunity, improving sleep, and defending against memory loss. Its product is absorbed through the skin to bypass gut malabsorption and is positioned as pharmaceutical-grade science offered at supplement pricing.

1 investor

Amalgent is a clinical-stage pain management company developing oral combination drug therapeutics that repurpose existing medications to improve the safety of severe pain treatment. It initially targets the US market.

1 investor

Amaros builds AmarosEngine, a precision intelligence platform that integrates ophthalmology clinics' EHR, practice management, and imaging systems to unify ophthalmic data and generate real-world evidence and insights. It serves CROs, pharma, biotech, and eye-care clinics across the ophthalmic ecosystem for clinical trials, point-of-care treatment, and commercial growth, primarily in the United States with global expansion.

1 investor

Amayu operates a platform in Germany that connects patients with ketamine therapy for psychiatric and chronic conditions, combining medical ketamine treatments delivered by independent partner physicians with accompanying psychological support. It coordinates in-practice sessions and online video consultations for conditions such as depression, anxiety, trauma, OCD, chronic pain, and addiction, currently offering treatment in Berlin with planned expansion to other German cities.

1 investor

Amazentis is a Swiss longevity-biotech company that developed Mitopure, a proprietary high-purity form of the postbiotic Urolithin A shown in human trials to support mitochondrial health via mitophagy. It brings the molecule to consumers through its Timeline brand of supplements and skincare, and partners with companies including Nestlé Health Science and L'Oréal.

1 investor

AmbiMass Kft. is a Hungarian company specializing in mass spectrometry, including precise measurement, sample preparation, and data evaluation. It also integrates laser optical systems into mass spectrometry applications and develops standalone analytical systems, drawing on a multidisciplinary team of engineers, software developers, chemists, and biologists.

1 investor

AmbioPharm is a contract manufacturer of custom peptide active pharmaceutical ingredients (APIs), providing process development, scale-up, and cGMP manufacturing for late-stage clinical and commercial peptide products. It serves pharmaceutical and biotech companies, clinical research labs, universities, and cosmetic formulators, and is expanding its North Augusta, South Carolina campus for U.S.-based commercial-scale peptide production.

1 investor

Ambrosia Biosciences is a drug discovery company developing orally delivered, small molecule therapies for obesity and other metabolic disorders. It operates U.S.-based biology and chemistry laboratories along with an NMR facility and structural biology and computational chemistry capabilities to advance programs from hit to IND.

1 investor

The Acid Maltase Deficiency Association (AMDA) is a nonprofit organization that funds research, provides educational resources, and supports early diagnosis and care for individuals and families affected by Pompe disease, a rare genetic condition. It works with global experts, industry, and policymakers and offers webinars, peer support sessions, research grants, and patient advocacy for the Pompe disease community.

1 investor

Amelieff provides bioinformatics support to research and development clients through IT systems, data analysis, training programs, and consulting. It also offers study sessions, seminars, and on-demand educational videos on bioinformatics.

1 investor

Amend Surgical develops suture-less nerve repair devices using resorbable hydrogel technology licensed from Harvard's Wyss Institute. The company serves surgeons and hospitals treating peripheral nerve injuries.

1 investor